Aavigen Gmbh
AaviGen GmbH is a Heidelberg-based preclinical-stage biotech developing heart-targeted AAV gene therapies for cardiovascular disease, using its proprietary next-CAP capsid engineering platform and lead product AVG-101 to address heart failure with organ-specific, low-dose cardiac gene delivery.
- Company typePrivate
- Founded2019
- HeadquartersHeidelberg, Germany
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Aavigen Gmbh does
AaviGen GmbH is a preclinical-stage biotechnology company founded in 2019 and headquartered in Heidelberg, Germany, that develops heart-targeted adeno-associated virus (AAV)-based gene therapies for cardiovascular and cardiopulmonary diseases. The company operates the proprietary next-CAP platform, which combines experimental and bioinformatic methodologies to molecularly engineer AAV capsids with organ-specific tropism, iteratively selecting for manufacturability, transduction, and transgene expression in human-relevant model systems. The resulting portfolio of heart-specific vectors is designed to enable precise, low-dose cardiac gene therapy via peripheral intravenous infusion, addressing the central challenge of off-target delivery and dose-dependent toxicity that constrains conventional AAV approaches.
The company's therapeutic pipeline is organized around five molecular target modules in heart failure: plasma membrane calcium channels, sarcoplasmic reticulum calcium release, mitochondrial energy metabolism, the contractile apparatus (cardiac titin), and beta-adrenergic signaling. Its lead candidate, AVG-101, uses the heart-specific AAV technology to target underlying molecular causes of cardiac muscle dysfunction. Manufacturing is outsourced to CDMO partner SK pharmteco under a multi-year preferred-partner agreement, and a 2026 research collaboration with Circio Holding ASA combines Circio's circVec circular RNA platform with AaviGen's capsids to pursue next-generation low-dose cardiac gene therapy.
AaviGen's business model is consistent with an early-stage biotech: revenue is expected to derive from out-licensing, co-development partnerships, and milestone payments once products advance, with no commercial products or disclosed pricing in market. The company is private, employs 1-10 people, has not publicly disclosed any institutional funding rounds, and is led by a founding team (Prof. Patrick Most, CEO; Dr. Martin Busch, COO; Prof. Marc Lerchenmüller, CFO; Prof. Hugo Katus, CMO) whose prior work includes the Troponin T test and the founding of InoCard (subsequently acquired by uniQure N.V.). It addresses an unmet need of 64.3 million heart failure patients globally with 67-75% five-year mortality, targeting pharmaceutical partners, CDMOs, and academic medical centers through executive-led business development rather than a commercial sales motion.
Aavigen Gmbh firmographics
Firmographics- Name
- Aavigen Gmbh
- Legal name
- AaviGen GmbH
- Website
- https://aavigen.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- AaviGen GmbH is a Heidelberg-based preclinical-stage biotech developing heart-targeted AAV gene therapies for cardiovascular disease, using its proprietary next-CAP capsid engineering platform and lead product AVG-101 to address heart failure with organ-specific, low-dose cardiac gene delivery.
- Ownership category
- akta.pro rank
Aavigen Gmbh industry classification
Industry- Product category
- Cardiovascular Gene Therapy / Biotechnology
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- AAV Vector Gene Therapy Developers (HLAAACAA)
- akta.pro secondary industries
- Cardiometabolic & Other Systemic Gene Therapies (HLAAACAI), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)
Keywords
Where Aavigen Gmbh is headquartered
LocationHeadquarters
- HQ city
- Heidelberg
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
Aavigen Gmbh business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Revenue model
- Gene Therapy Development and Commercialization: As a preclinical-stage biotech company, AaviGen is in the early phases of developing its gene therapy pipeline for heart failure and cardiovascular diseases. Revenue will derive from licensing deals, co-development partnerships, and eventual product commercialization once therapies receive regulatory approval.
- Strategic Partnerships and Manufacturing Agreements: Revenue may be generated through milestone payments and development fees from strategic partnerships such as the SK pharmteco manufacturing agreement and the Circio research collaboration.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Aavigen Gmbh product offering
Product offeringCore offering
AaviGen GmbH is a preclinical-stage biotechnology company that develops heart-targeted adeno-associated viral (AAV) vector-based gene therapies for cardiovascular and cardiopulmonary diseases. Its proprietary next-CAP platform engineers heart-specific AAV capsids used to build a cardiac gene therapy pipeline led by AVG-101 for heart failure, addressing five molecular target modules including calcium signaling, mitochondrial energetics, and contractile apparatus function.
Product overview
AaviGen is a preclinical-stage biotechnology company developing a portfolio of gene therapies for cardiovascular diseases. The company operates its next-CAP Platform to engineer proprietary heart-specific Adeno-Associated Viral (AAV) vectors, which form the foundation of its cardiac gene therapy pipeline. The lead product candidate is AVG-101 for heart failure treatment. The pipeline addresses five therapeutic target areas: plasma membrane calcium channels, sarcoplasmic reticulum calcium cycling, mitochondrial energy metabolism, contractile apparatus (cardiac titin), and beta-adrenergic signaling. The company leverages partnerships for manufacturing (SK pharmteco) and research collaborations (Circio) to advance its vector technology.
Differentiator
Problem solved
Functional benefit
Products and services
- next-CAP Platform Proprietary hybrid platform that integrates cutting-edge experimental and bioinformatic technologies to molecularly engineer AAV capsids, creating vector libraries with high quantitative and qualitative diversity for organ-specific gene therapy delivery. Intrinsically selects for manufacturability, transduction, and transgene expression through iterative systemic selection in human-relevant model systems.
- AVG-101 Lead gene therapy product for the treatment of heart failure, leveraging AaviGen's proprietary heart-specific AAV vector technology to target and reverse underlying molecular causes of heart muscle dysfunction, administered via peripheral intravenous infusion.
- Heart-Specific AAV Vectors Proprietary organ-specific adeno-associated viral vectors engineered for precise cardiac tropism, enabling targeted delivery of therapeutic genes to cardiomyocytes with unprecedented safety profiles by minimizing off-target organ delivery.
- Cardiac Gene Therapy Pipeline (Five Therapeutic Modules) Therapeutic target pipeline addressing five key cardiac molecular areas: (1) plasma membrane voltage-dependent calcium channels, (2) sarcoplasmic reticulum ryanodine receptor calcium release, (3) mitochondria and energy metabolism via F1/0-ATPase, (4) contractile apparatus including cardiac titin and myofilament calcium sensitivity, and (5) beta-adrenergic signaling for desensitized downstream signaling.
Companies that use Aavigen Gmbh
Customer profileSegments1 record
Ideal customer profiles3 records
Aavigen Gmbh technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Aavigen Gmbh partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Circio Holding ASAcoreCircio and AaviGen announced a three-stage research collaboration to develop next-generation AAV gene therapy vectors specifically engineered for targeted, low-dose heart gene therapy. The partnership combines Circio's circVec circular RNA platform (demonstrating 40-fold enhanced gene expression in heart tissue) with AaviGen's proprietary heart-targeted AAV capsids. Stages include: (1) production of novel AAVs combining both technologies, (2) in vitro testing and characterization, and (3) in vivo validation focusing on biodistribution and gene expression profiles.
- Will AdamsminorWill Adams served as Lead Mentor for AaviGen during the German Accelerator U.S. Market Access Life Sciences Program and subsequently joined the AaviGen Advisory Board. He brings U.S. market expertise and industry connections as the company expands globally.
- Prof. Dr. Toni CathomenminorProf. Dr. Toni Cathomen joined AaviGen's Scientific Advisory Board as an expert in targeted gene editing. He is Professor of Cell and Gene Therapy and Director of the Institute for Transfusion Medicine and Gene Therapy at the University Medical Center, University of Freiburg. His expertise in designer nucleases (CRISPR-Cas) and gene therapy applications complements AaviGen's AAV vector platform.
- SK pharmtecocoreSK pharmteco, a global contract development and manufacturing organization (CDMO) for small molecules and advanced therapies, entered a multi-year manufacturing agreement as the preferred manufacturing partner for AaviGen's lead gene therapy product AVG-101 for heart failure. SK pharmteco provides process development and manufacturing of adeno-associated viral-based gene therapies, with recent investments in expanding manufacturing capacity to support development through commercialization.
- University of HeidelbergminorMultiple founding team members (Prof. Patrick Most heads the Molecular and Translational Cardiology Division; Prof. Hugo Katus is Director of Cardiology) maintain academic affiliations with the University of Heidelberg. The company was founded on research and translational expertise developed within this academic institution.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Aavigen Gmbh competitors and assessment
Company assessmentBroad incumbents
- uniQure N.V. uniQure is an established gene therapy company where AaviGen's CEO previously led cardiac gene therapy development after acquiring InoCard. It is a relevant incumbent comparable given overlapping AAV platform and cardiovascular franchise, but operates at a much larger scale across multiple indications.
- REGENXBIO: REGENXBIO is a leading AAV gene delivery platform company with NAV technology used across many partners including cardiac programs. It is comparable as a platform-level AAV peer even though its primary commercial focus is ophthalmology and rare disease.
- Renovacor (acquired by Rocket Pharmaceuticals): Renovacor developed AAV-based gene therapies for cardiomyopathy associated with BAG3 mutations and was acquired by Rocket Pharmaceuticals. Rocket itself is a broader gene therapy company with cardiac-relevant programs, making it a relevant comparable for the cardiac AAV niche AaviGen targets.
- Asklepios BioPharmaceutical (AskBio): AskBio, a Bayer subsidiary, develops AAV-based gene therapies across multiple therapeutic areas including cardiac indications (e.g., congestive heart failure programs). It represents a large, well-funded AAV platform incumbent with overlapping modality.
Direct peers
- Lexeo Therapeutics: Lexeo is a clinical-stage gene therapy company focused on cardiovascular diseases, including AAV-based therapies for cardiomyopathies and heart failure. It is the most direct competitor to AaviGen given overlapping cardiac indication focus and AAV delivery approach.
- Tenaya Therapeutics: Tenaya is developing genetic medicines for heart disease, including AAV-based gene therapies for cardiomyopathies and heart failure. Its pipeline targeting cardiac genetic and acquired disease states directly overlaps with AaviGen's therapeutic focus.
- DiNAQOR: DiNAQOR is a preclinical-to-clinical-stage platform company developing AAV gene therapies specifically for cardiac diseases. It is highly comparable to AaviGen given the shared heart-targeted AAV modality and pipeline ambition.
Emerging players
- Solid Biosciences: Solid Biosciences develops AAV gene therapies for cardiac and neuromuscular diseases, including programs for Duchenne muscular dystrophy with cardiac involvement. It overlaps with AaviGen on AAV modality and cardiac targeting, though it is at a later clinical stage.
- Kriya Therapeutics: Kriya is a gene therapy company developing AAV-based therapies across multiple therapeutic areas with a platform-engineering approach. It is a comparable AAV platform peer, though its current disclosed pipeline does not focus primarily on cardiac indications.
- Sardocor: Sardocor is an emerging cardiac gene therapy developer focused on AAV-based treatments for inherited and acquired heart diseases. It competes in the same cardiac AAV niche as AaviGen but at an earlier stage.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Aavigen Gmbh social profiles
Digital presenceAavigen Gmbh financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aavigen Gmbh leadership team
Management profileNumber of profiles
Profiles4 records
Aavigen Gmbh funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aavigen Gmbh M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aavigen Gmbh
What does Aavigen Gmbh do?
AaviGen GmbH is a preclinical-stage biotechnology company that develops heart-targeted adeno-associated viral (AAV) vector-based gene therapies for cardiovascular and cardiopulmonary diseases. Its proprietary next-CAP platform engineers heart-specific AAV capsids used to build a cardiac gene therapy pipeline led by AVG-101 for heart failure, addressing five molecular target modules including calcium signaling, mitochondrial energetics, and contractile apparatus function.
Is Aavigen Gmbh a public or private company?
Aavigen Gmbh is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Aavigen Gmbh founded?
Aavigen Gmbh was founded in 2019. It employs 1 to 10 people.
Where is Aavigen Gmbh based?
Aavigen Gmbh is headquartered in Heidelberg, Germany, in the Europe region.
How does Aavigen Gmbh make money?
Two revenue lines are on record. Gene Therapy Development and Commercialization is the primary driver. The others are strategic Partnerships and Manufacturing Agreements.
Who are Aavigen Gmbh's main competitors?
Broad incumbents on record are uniQure N.V., REGENXBIO, Renovacor (acquired by Rocket Pharmaceuticals) and Asklepios BioPharmaceutical (AskBio). Direct peers are Lexeo Therapeutics, Tenaya Therapeutics and DiNAQOR. Emerging players are Solid Biosciences, Kriya Therapeutics and Sardocor.
Does Aavigen Gmbh have an API?
No public API is recorded for Aavigen Gmbh.
What industry is Aavigen Gmbh in?
Aavigen Gmbh's product category is Cardiovascular Gene Therapy / Biotechnology. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers, with a secondary code of HLAAACAI, Cardiometabolic & Other Systemic Gene Therapies. Its NAICS code is 541714 and its SIC code is 3841.